Malignancies in Juvenile Idiopathic Arthritis: A Preliminary Report: Table 1.
Authors:
- Sasha BernatskySBSasha Bernatsky
- Ciaran M. DuffyCDCiaran M. Duffy
- Jeremy LabrecqueJLJeremy Labrecque
- Yvan St. PierreYPYvan St. Pierre
- Ann E. ClarkeACAnn E. Clarke
Open Access
- 15 January 2011
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 38 (4) , 760-763
Abstract
Objective. To present preliminary data on incidence of malignancy in juvenile idiopathic arthritis (JIA), compared to general population rates. Methods. We examined cancer occurrence within JIA registries at 3 Canadian pediatric rheumatology centers. The subjects in the clinic registries were linked to regional tumor registries to determine the occurrence of invasive cancers over the observation period (spanning 1974–2006). The total number of cancers expected was determined by multiplying the person-years in the cohort by age, sex, and calendar year-specific cancer rates. The standardized incidence ratio (SIR, ratio of cancers observed to expected) was generated, with 95% confidence intervals. Results. The study sample consisted of 1834 patients. The female proportion was 67.6%; average age at entry to cohort was 8.6 years (SD 5.1). The majority were Caucasian. Subjects contributed 22,341 patient-years (average 12.2, SD 7.8). Within this observation period, one invasive cancer occurred, compared to 7.9 expected (SIR 0.12, 95% CI 0.0, 0.70). This was a hematological cancer (Hodgkin’s lymphoma), representing a SIR for hematological malignancies of 0.76 (95% CI 0.02, 4.21). Conclusion. Only one invasive cancer was identified in this large sample of individuals with JIA, observed for an average of 12.2 years each. These data suggest that, at least in the initial years following diagnosis of JIA, the risk of invasive cancers overall is not markedly increased. The results do not rule out the possibility of a baseline increased risk of hematological malignancies.Keywords
This publication has 10 references indexed in Scilit:
- Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseasesAnnals of the Rheumatic Diseases, 2009
- Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?Arthritis & Rheumatism, 2009
- Long‐term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritisArthritis & Rheumatism, 2009
- Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national registerAnnals of the Rheumatic Diseases, 2009
- Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA RegistryAnnals of the Rheumatic Diseases, 2009
- Focus on adverse events of tumour necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patientsAnnals of the Rheumatic Diseases, 2008
- Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritisArthritis & Rheumatism, 2008
- Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label studyAnnals of the Rheumatic Diseases, 2003
- Risk of malignancy among patients with rheumatic conditionsInternational Journal of Cancer, 2000
- Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control studyBMJ, 1998